Want to join the conversation?
$BIIB expects R&D expense for 2016 to be approx. 19% to 20% of sales, including about $100MM earmarked for business development activity. The Company plans to continue to invest in a number of R&D programs across late-stage pipeline during 2016, including aducanumab for Alzheimer's disease and nusinersen for spinal muscular atrophy.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!